| Objective:To investigate the role of serum Cystatin C in the assessment of its condition and prognosis,and to judge the progression and prognosis of patients with chronic pulmonary heart disease.Methods:A retrospective study was conducted on 108 patients with chronic pulmonary heart disease who were hospitalized from Department of Respiratory Medicine,Yanbian University Hospital,from January 2012 to December 2016,and 32 healthy subjects and were grouped on the clinical data.Results:1.Compared with the control group,the levels of serum Cystatin C and uric acid were significantly increased in the patients with decompensated period of acute exacerbation of chronic pulmonary heart disease,and the difference was statistically significant(P<0.01),and the levels of serum Cystatin C and uric acid in patients with decompensated period were significantly higher than those in the patients with compensatory stage(P<0.01).2.There was difference between the cystatin C(1.27 ± 0.42)in the decompensated patients with chronic cor pulmonale and the cystatin C(1.04 ± 0.28)in the compensatory group,which was statistically significant(P<0.01).There was significant difference between uric acid(303.50 ± 130.08)in the decompensated group and uric acid(241.33 ± 122.65)in the compensatory group(P<0.05).There was significant difference(P<0.01)in the arterial blood oxygen pressure between the decompensated group(54.72 ± 16.80)and the compensatory group(75.63 ± 16.55).There was significant difference(P<0.01)in hyper-sensitive C-reactive protein between the decompensated group(53.31 ± 36.98)and the compensated group(27.74±34.91).3.The levels of cystatin C before(1.27 ± 0.42)and after treatment(1.06 ± 0.44)in patients with decompensated pulmonary heart disease were significantly different(P<0.01).The levels of uric acid before(303.50 ± 130.08)and uric acid after treatment(227.16 ± 110.67)were statistically significant(P<0.01).The difference of Pa02 before(54.72 ± 16.80)and after treatment(69.06 ± 18.61)was statistically significant(P<0.01).Before treatment,CRP(53.31 ± 36.98)was significantly higher than that of CRP(25.30 ± 34.77)after treatment(P<0.01).4.There was a positive correlation between serum Cystatin C and uric acid before treatment(r = 0.386,P<0.01).The regression equation was y = 135.54x +105.61.The serum Cystatin C was negatively correlated with PaO2 in patients with chronic pulmonary heart disease.(R =-0.789,P<0.01).The regression equation was y ?-39.342x + 110.07.The serum Cystatin C was positively correlated with CRP in the patients with decompensated pulmonary heart disease.(R = 0.842,P<0.01),and the regression equation was y = 88.36x-69.758.Conclusion:1.Compared with healthy people,chronic pulmonary heart disease in patients with serum Cystatin C,uric acid levels increased.2.For patients suffering from a chronic pulmonary heart disease,when their pulmonary function improves,the level of serum cystatin C and uric acid was significantly reduced and arterial blood oxygen pressure increased,indicating that the changes of the level of serum cystatin C and uric acid can reflect patients' pulmonary function.3.There was a negative correlation between serum Cystatin C and PaO2 in patients with pulmonary heart disease,and positively correlated with uric acid and CRP.4.Serum Cystatin C and uric acid can be used to assess the severity of chronic pulmonary heart disease and one of the indicators after the disease. |
PDF Full Text Request